PT - JOURNAL ARTICLE AU - Green, Lydia AU - Hamilton, Noémie AU - Elpidorou, Marilena AU - Harris, Erica L. AU - Douglas, Andrew AU - Ounap, Katrin AU - Maroofian, Reza AU - Rose, Ailsa M.S. AU - Elworthy, Stone AU - Renshaw, Stephen A AU - Low, Elizabeth C. AU - Prescott, Trine AU - Soberg, Kristoffer AU - Al-Maawali, Almunder AU - Al-Zuhaibi, Sana AU - Futaisi, Amna Al AU - Calame, Daniel AU - Al-Thihli, Khalid AU - Sheridan, Eamonn G. AU - Johnson, Colin A. AU - Livingston, John AU - Crow, Yanick J. AU - Poulter, James A TI - Biallelic mutation of <em>SUPV3L1</em> causes an inherited leukodystrophy-associated neurodevelopmental disorder due to aberrant mitochondrial double stranded RNA processing AID - 10.1101/2023.07.03.23291502 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.03.23291502 4099 - http://medrxiv.org/content/early/2023/07/03/2023.07.03.23291502.short 4100 - http://medrxiv.org/content/early/2023/07/03/2023.07.03.23291502.full AB - Inherited white matter disorders (IWMD), or leukodystrophies (LD), are genetic disorders primarily affecting the white matter of the central nervous system (CNS), with or without peripheral nerve involvement. Recent developments in novel gene discovery has led to a greater understanding of myelin biology, with an increasing number of proteins with a wide variety of functions, involved in myelin development, maintenance and function. Here we describe 12 individuals from 9 families diagnosed with a neurodevelopmental disorder in whom biallelic variants in SUPV3L1 have been identified. SUPV3L1 encodes an RNA helicase with previous studies showing a key role in the mitochondrial degradosome. We found patient mutations led to an increase in mitochondrial double stranded RNAs in human cells and supv3l1 knock-out zebrafish confirmed a role in neurodevelopment, with gross defects identified in mitochondrial biogenesis and microglial function. Zebrafish displayed a significant activation of the Type 1 interferon pathway, which was later also confirmed by qPCR on blood RNA from biallelic SUPV3L1 patients. Altogether we describe the clinical spectrum associated with biallelic SUPV3L1 mutations and show the mutations identified result in increased mitochondrial double stranded RNA, altered mitochondrial biogenesis, dysplastic microglia and activation of the type 1 interferon innate immune pathway.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by a Sir Jules Thorn Award for Biomedical Research (JTA/09 to E.G.S and C.A.J.), a University of Leeds Academic Fellowship (to J.A.P), a University of Leeds PhD studentship (to M.E) and a White Rose Universities Collaboration grant (to N.H. and J.A.P). J.A.P is supported by a UKRI Future Leaders Fellowship (MR/T02044X/1). N.H. is supported by a grant from The Legacy of Angels. S.A.R is supported by a Medical Research Council grant to SHIELD consortium MR/NO2995X/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Yorkshire &amp; Humber Leeds East Research Ethics Committee (REC ref. 18/YH/0070).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors